Measurement of residual disease (MRD) is one of the most reliable predictors of treatment outcomes for patients with leukemia, lymphoma, and myeloma. Because of this, global central laboratories like Q2
Solutions will have an increasingly important role to play in MRD testing.
In this complimentary insight brief
you'll learn how 3 key technologies – Next Generation Sequencing, Flow Cytometry, and Polymerase Chain Reaction – help pharmaceutical and biotechnology companies predict better treatment outcomes through MRD testing.
today to discover how we can use our deep scientific expertise and global laboratory footprint to improve patient care in your MRD testing programs.
About the Authors:
, Ph.D., Chief Scientific Officer, Q2
, Director, Scientific Advisor, Flow Cytometry
, Ph.D., Director, Translational Genomics
, Ph.D., Senior Director and Global Head, Translational Genomics
, B.Sc., Scientific Advisor, Oncology and Companion Diagnostics
, M.D., M.Sc., FCAP, Director of Hematopathology